Shiral S. Gangadin

To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial

Marieke Begemann, Ilse A. Thompson, Wim Veling et al. · Trials · 2020 · 72 citations · Full text

Pharmacy, Pharmacotherapy, Psychiatry +17

Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse

Iris E. Sommer, Bodyl A. Brand, Shiral S. Gangadin et al. · Schizophrenia Bulletin · 2022 · 69 citations · Full text

Medicine, Gynecology, Psychiatry +17

Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial

Iris E. Sommer, Shiral S. Gangadin, Lot D. de Witte et al. · Schizophrenia Bulletin · 2021 · 49 citations · Full text

Medicine, Pharmacology, Psychiatry +15

Longitudinal clinical and functional outcome in distinct cognitive subgroups of first-episode psychosis: a cluster analysis

Priscilla P. Oomen, Marieke Begemann, Bodyl A. Brand et al. · Psychological Medicine · 2021 · 44 citations · Full text

Medicine, Psychiatry, Psychology +17

Reduced resting state functional connectivity in the hippocampus-midbrain-striatum network of schizophrenia patients

Shiral S. Gangadin, Wiepke Cahn, Thomas W. Scheewe et al. · Journal of Psychiatric Research · 2021 · 27 citations · Full text

Medicine, Neuroscience, Psychiatry +17